MAGEA3

Function

Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a repressor of autophagy (PubMed:20864041, PubMed:31267705). May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex (PubMed:17942928, PubMed:20864041). May play a role in embryonal development and tumor transformation or aspects of tumor progression (PubMed:17942928, PubMed:20864041). In vitro promotes cell viability in melanoma cell lines (PubMed:17942928). Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes (PubMed:8113684).

Post-translational modifications

Ubiquitinated by the DCX(DCAF12) complex specifically recognizes the diglutamate (Glu-Glu) at the C-terminus, leading to its degradation.

Tissue Specificity

Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta. Never expressed in kidney tumors, Leukemias and lymphomas.

Alternative names

MAGE3, MAGEA3, Melanoma-associated antigen 3, Antigen MZ2-D, Cancer/testis antigen 1.3, MAGE-3 antigen, CT1.3

Database links

swissprot:P43357 omim:300174 entrezGene:4102

Other research areas

• Immuno-oncology